Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-13 7:06 pm Sale | 2025-09-30 | 13G | NovoCure Limited NVCR | Capital World Investors | 2,000,000 1.800% | -4,382,848 (-68.67%) | Filing History |
| 2025-11-07 4:00 pm Purchase | 2025-09-30 | 13G | NovoCure Limited NVCR | Soleus Capital Master Fund, L.P. | 9,644,872 8.600% | 2,740,570 (+39.69%) | Filing History |
| 2025-08-13 12:56 pm Purchase | 2025-06-30 | 13G | NovoCure Limited NVCR | Capital World Investors | 6,382,848 5.700% | 3,105,852 (+94.78%) | Filing History |
| 2025-08-05 5:00 pm Purchase | 2025-06-30 | 13G | NovoCure Limited NVCR | Soleus Capital Master Fund, L.P. | 6,904,302 6.200% | 1,382,888 (+25.05%) | Filing History |
| 2025-07-07 1:42 pm Sale | 2025-06-30 | 13G | NovoCure Limited NVCR | Capital International Investors | 0 0.000% | -8,896,076 (Position Closed) | Filing History |
| 2025-04-23 8:00 pm Purchase | 2025-03-31 | 13G | NovoCure Limited NVCR | BlackRock Inc. BLK | 9,083,620 8.300% | 9,083,620 (New Position) | Filing History |
| 2025-04-01 5:00 pm Purchase | 2025-03-31 | 13G | NovoCure Limited NVCR | Soleus Capital Master Fund, L.P. | 5,521,414 5.000% | 5,521,414 (New Position) | Filing History |
| 2024-07-10 1:14 pm Purchase | 2024-06-28 | 13G | NovoCure Limited NVCR | The Vanguard Group | 11,127,354 10.340% | 1,368,267 (+14.02%) | Filing History |
| 2024-07-08 4:32 pm Purchase | 2024-06-30 | 13G | NovoCure Limited NVCR | BlackRock Inc. BLK | 12,215,856 11.400% | 3,423,821 (+38.94%) | Filing |
| 2024-02-13 5:09 pm Purchase | 2023-12-29 | 13G | NovoCure Limited NVCR | The Vanguard Group | 9,759,087 9.130% | 211,751 (+2.22%) | Filing History |
| 2024-02-09 6:14 pm Sale | 2024-02-07 | 13G | NovoCure Limited NVCR | Capital World Investors | 3,276,996 3.100% | -2,557,084 (-43.83%) | Filing History |
| 2024-02-09 6:03 pm Purchase | 2024-02-07 | 13G | NovoCure Limited NVCR | Capital International Investors | 8,896,076 8.300% | 740,167 (+9.08%) | Filing History |
| 2024-02-09 11:32 am Purchase | 2023-12-31 | 13G | NovoCure Limited NVCR | BlackRock Inc. BLK | 8,792,035 8.200% | 1,186,610 (+15.60%) | Filing |
| 2024-02-09 09:28 am Purchase | 2024-02-08 | 13G | NovoCure Limited NVCR | FMR LLC | 15,962,765 14.937% | 219,251 (+1.39%) | Filing History |
| 2023-12-11 06:19 am Sale | 2023-12-11 | 13G | NovoCure Limited NVCR | Capital World Investors | 5,834,080 5.500% | -7,065,315 (-54.77%) | Filing History |
| 2023-11-09 06:15 am Sale | 2023-10-31 | 13G | NovoCure Limited NVCR | BAILLIE GIFFORD & CO | 5,095,777 4.770% | -3,768,065 (-42.51%) | Filing History |
| 2023-02-13 3:54 pm Sale | 2023-02-14 | 13G | NovoCure Limited NVCR | Capital International Investors | 8,155,909 7.800% | -3,375,166 (-29.27%) | Filing History |
| 2023-02-13 2:49 pm Purchase | 2023-02-14 | 13G | NovoCure Limited NVCR | Capital World Investors | 12,899,395 12.300% | 176,181 (+1.38%) | Filing History |
| 2023-02-09 12:01 pm Purchase | 2023-02-09 | 13G | NovoCure Limited NVCR | FMR LLC | 15,743,514 14.999% | 5,006,810 (+46.63%) | Filing History |
| 2023-02-09 11:27 am Purchase | 2022-12-30 | 13G | NovoCure Limited NVCR | The Vanguard Group | 9,547,336 9.100% | 1,654,023 (+20.95%) | Filing History |